Compare ENVX & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVX | TWST |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 2018 |
| Metric | ENVX | TWST |
|---|---|---|
| Price | $7.74 | $45.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $17.14 | ★ $44.67 |
| AVG Volume (30 Days) | ★ 6.0M | 1.2M |
| Earning Date | 02-18-2026 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $30,273,000.00 | ★ $376,572,000.00 |
| Revenue This Year | $34.74 | $16.69 |
| Revenue Next Year | $104.90 | $15.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 45.98 | 20.32 |
| 52 Week Low | $5.27 | $23.30 |
| 52 Week High | $16.49 | $55.33 |
| Indicator | ENVX | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 78.70 |
| Support Level | $7.29 | $39.13 |
| Resistance Level | $8.50 | $42.60 |
| Average True Range (ATR) | 0.59 | 2.35 |
| MACD | -0.01 | 0.80 |
| Stochastic Oscillator | 26.87 | 94.59 |
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.